Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC

Stopped Study terminated prematurely due to business reasons. Participants are no longer examined or receiving intervention.

Conditions

• Triple Negative Breast Neoplasms

Interventions

• DRUG: 350 mg leronlimab
• DRUG: 525 mg leronlimab
• DRUG: 700 mg leronlimab
• DRUG: AUC 5 Carboplatin
• DRUG: Maximum Tolerated Dose (MTD) of leronlimab

Sponsor

CytoDyn, Inc.

Collaborators

• [object Object]